STOCK TITAN
  1. Home
  2. News
  3. PASG

Passage Bio, Inc. - PASG STOCK NEWS

Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.

Passage Bio, Inc. (NASDAQ: PASG) delivers cutting-edge gene therapies targeting rare central nervous system disorders through innovative AAV vector technology. This news hub provides investors and researchers with timely updates on clinical advancements, strategic partnerships, and operational developments shaping the company's trajectory in genetic medicine.

Access authoritative reporting on PASG's lead programs including PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia. Our curated news collection features regulatory milestones, trial data disclosures, and analysis of licensing agreements with academic and industry partners.

Key updates cover three critical areas: clinical trial progress across neurodegenerative targets, research collaborations enhancing therapeutic platforms, and strategic operational decisions supporting sustainable development. Bookmark this page for consolidated access to PASG's evolving position in gene therapy innovation.

News

Passage Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Passage Bio, Inc. (PASG) will participate in investor conferences like TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference to discuss their clinical-stage genetic medicines for neurodegenerative diseases. A webcast will be available for investors on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences
-
News

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Summary
Passage Bio, Inc. (PASG) announced that its CEO will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The event will be live webcasted and available for replay on the company's website. The focus of the company is on genetic medicines for neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
-
News

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Rhea-AI Summary
Passage Bio, Inc. (Nasdaq: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations. The data showcased PBFT02's ability to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment. The company also shared strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.38%
Tags
clinical trial
News

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Passage Bio, Inc. (Nasdaq: PASG) grants 10,400 shares of common stock as an inducement award to a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.628 per share, equal to the closing price on November 15, 2023. The shares will vest over four years, with 25% vesting after one year, and the remainder in 36 equal monthly installments, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
News

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Rhea-AI Summary
Passage Bio, Inc. (PASG) reports progress in clinical trials for FTD and GM1 treatment, with a strong financial position and extended cash runway. The company expects to present initial safety and biomarker data from three Cohort 1 patients in the upliFT-D trial for FTD in Q4 2023 and from Dose 3 patients in the Imagine-1 trial for GM1 in mid-2024. With a robust balance sheet, Passage Bio is well-positioned to achieve meaningful clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference

Rhea-AI Summary
Passage Bio, Inc. (NASDAQ: PASG) announced that its CEO, William Chou, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on November 6, 2023 at 2:30 p.m. ET. The event will be webcasted live on Passage Bio's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.93%
Tags
conferences
News

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Passage Bio grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
News

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference

Rhea-AI Summary
Passage Bio's CEO to participate in fireside chat at Chardan's Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
-
News

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
earnings
News

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Rhea-AI Summary
Passage Bio announces new interim safety, biomarker, and survival data from the Imagine-1 clinical study. Dose 2 of PBGM01 shows substantial improvements in CSF biomarkers and achieves normal levels of CSF β-Gal activity and GM1 gangliosides. Initial evidence of improved survival relative to natural history data. Dose 3 data expected by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
clinical trial
Stock PASG logo
Passage Bio, Inc.

Nasdaq:PASG

PASG Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PASG Stock Data

20.51M
54.96M
0.48%
60.63%
2.93%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PHILADELPHIA